This guide is currently available in English. A Spanish version is in progress.
Sourcing Exosomes in Alaska
Licensed Alaska practices order Kimera exosome material from ExaVeyra for topical aesthetic use, shipped frozen from Florida with a Certificate of Analysis and lot traceability on every vial. Alaska buyers need their own professional license and NPI; the nonresident wholesale drug distributor license is the supplier’s obligation, not the purchaser’s.
Alaska is one of the most practitioner-friendly states in this series: advanced practice registered nurses are licensed independent practitioners, there is no stem cell statute to parse, and the state levies no statewide sales tax. The details worth knowing are the supplier’s licensing, the PA collaborative plan, and how cold-chain freight actually reaches the state.
At a glance
| Question | Answer |
|---|---|
| Does ExaVeyra ship to Alaska? | Yes. Shipped frozen from Florida, as we do to all 50 states |
| Cold-chain shipping from Florida | Overnight shipping; arrival can take 1 to 3 business days |
| State regenerative-medicine statute | None |
| Does that statute reach exosomes? | No. Its definition is written around cells; exosomes are acellular and governed federally |
| Physician delegation required to hand off medical acts | No |
| Who holds the licensure to ship into the state | The pharmacy partner and the tissue bank that ship, not the purchasing practice |
| What ExaVeyra supplies here | Kimera exosome material; compounded preparations available through the 503A pharmacy partner |
| Last reviewed | 16 October 2026 |
Ordering from Alaska
ExaVeyra ships to licensed practices in all 50 states, Alaska included. Licensure for shipping into the state is held by the entities that ship: our 503A pharmacy partner holds nonresident pharmacy licenses in 33 jurisdictions, including Puerto Rico, and exosome material ships from a registered tissue bank licensed to ship to all 50 states and Puerto Rico. Your practice orders against its own professional license and NPI and needs no wholesale permit to purchase.
What your practice provides
- An active Alaska professional license in good standing, verifiable through the professional license search of the Division of Corporations, Business and Professional Licensing.
- A valid NPI, which ExaVeyra verifies at account setup.
- A signed professional-use acknowledgment on file for exosome material.
- No statewide resale certificate exists because Alaska levies no statewide sales tax; a practice in a municipality that levies a local sales tax keeps its municipal registration and resale documentation in order where it buys for resale.
How the state permits wholesale distribution
Alaska licenses wholesale drug distributors through the Board of Pharmacy, within the Division of Corporations, Business and Professional Licensing. The nonresident category is recent: regulations adopted in June 2019 and effective 31 October 2019 added nonresident wholesale drug distributor, outsourcing facility, and third-party logistics provider licenses, and a distributor holds its license before shipping, mailing, or delivering prescription drugs to an Alaska licensee or advertising in the state, with an in-state agent appointed. The regime covers prescription drugs, and the license sits with the distributor, not with the purchasing practice.
AS 08.80; 12 AAC 52.610 to 12 AAC 52.697 · Alaska Board of Pharmacy, Division of Corporations, Business and Professional Licensing
Alaska regenerative-medicine law
Alaska has not enacted a statute specific to stem cell or regenerative therapies. Practice in this area is governed by the state's general medical practice and professional licensing rules, alongside federal law.
No Alaska statute addresses unapproved regenerative therapy, so federal law is the only layer that governs it here. The nearest enactment is the Alaska Right to Try Act (HB 43, signed July 2018), which made Alaska the 41st and final state to adopt one before the federal law: it lets a terminally ill patient, with physician involvement and written informed consent, access an investigational drug, biological product, or device that has completed Phase 1 trials. It is a terminal-illness access law, not a stem cell or regenerative medicine authorization. Practice in this area is governed by the Medical Practice Act (AS 08.64), the Nurse Practice Act (AS 08.68), and the boards that administer them, alongside federal law.
How this applies to exosomes
Alaska has no stem cell authorization law like Florida, Texas, or Georgia, no disclosure law like California, and no documentation statute like Tennessee; its Right to Try Act is sometimes raised in this context and is a terminal-illness access law that names no cell or tissue category at all. There is therefore no Alaska definition to read exosomes into or out of, and exosomes are acellular extracellular vesicles that even the cell-focused statutes of other states do not reach. Exosome products in Alaska are governed by federal law, under which no exosome product has been approved by the FDA for administration to humans. ExaVeyra supplies Kimera material for topical aesthetic use by licensed practitioners, with full COA and lot documentation.
Who can handle product in a Alaska practice
Because Alaska APRNs hold independent authority, there are two workable structures rather than one: an APRN-led practice operating within APRN scope, or a physician-led practice delegating conventionally, with a physician needed where a procedure falls outside APRN scope or a payer requires one. Physician assistants always need a board-approved collaborative plan. All the professions here are licensed within one agency, the Division of Corporations, Business and Professional Licensing, so license verification runs through a single search.
| Role | Scope under state law |
|---|---|
| MD / DO | Physicians licensed by the Alaska State Medical Board under AS 08.64 may perform medical acts within their scope and are the source of delegation to staff who do not hold independent authority. |
| NP / APRN | Alaska advanced practice registered nurses are licensed independent practitioners: no collaborative agreement or physician protocol is required, and an APRN holds independent prescriptive authority, including controlled substances with the board’s authorization. An APRN-led practice evaluates and orders within its own scope. |
| PA | Physician assistants practice under a collaborative plan on file with and approved by the State Medical Board (12 AAC 40.400 and 40.408), naming a primary collaborating physician and at least one alternate, and may not practice without at least one collaborative relationship in place. |
| RN | Registered nurses may perform delegated treatments within their scope and under an order from a provider with authority to issue one. An RN does not evaluate the patient or set the treatment plan. |
Good faith examination
Alaska expects a patient evaluation by a provider with authority to conduct it, and an order, before a delegated treatment is administered. That provider can be a physician, an APRN acting independently, or a PA within a collaborative plan. Confirm current expectations with the State Medical Board and the Board of Nursing, since this area is governed by board interpretation rather than a single statute.
Ownership and clinic licensing
Alaska does not enforce a corporate practice of medicine doctrine of the Texas or New York kind, and no statute mandates physician-only ownership of a medical business. The constraint is entity-specific: a professional corporation formed under the Professional Corporation Act (AS 10.45) must keep its shares with licensed professionals, but that form is optional. Because the position rests on what is absent from statute rather than on a bright-line rule, confirm structure with Alaska counsel before opening.
Cold chain into Alaska
Shipments leave Florida frozen under validated temperature monitoring. A package in transit over a weekend waits in the carrier network, so practices in Alaska order around weekend and holiday closures.
| Metro | County | Notes |
|---|---|---|
| Anchorage | Anchorage Municipality | Home to roughly four in ten Alaskans and the state’s air cargo hub. |
| Fairbanks | Fairbanks North Star Borough | Interior hub with a university and regional medical presence. |
| Juneau | City and Borough of Juneau | Capital market, reached by air and sea rather than road. |
| Wasilla and Palmer | Matanuska-Susitna Borough | Fast-growing commuter region north of Anchorage. |
| Kenai and Soldotna | Kenai Peninsula Borough | Peninsula market south of Anchorage on the road system. |
- Alaska orders of fifteen or more cold-chain units ship free nationwide; see the volume program for current thresholds.
- Each shipment arrives with the manufacturer’s handling instructions and the lot’s Certificate of Analysis; store to the labeled conditions on arrival.
- Overnight service to Alaska travels by air, and a practice outside the Anchorage, Fairbanks, or Juneau hub areas plans for the connecting leg when timing an order.
Practice types we supply in Alaska
Alaska licensing and verification
Alaska State Medical Board
Licenses physicians and approves physician assistant collaborative plans.
Alaska Board of Nursing
Licenses RNs and APRNs; Alaska APRNs are licensed independent practitioners.
Alaska Board of Pharmacy
Issues the nonresident wholesale drug distributor licenses held by suppliers shipping in.
Alaska Department of Revenue, Tax Division
Alaska levies no statewide sales tax; local sales taxes are municipal matters.
Alaska sourcing questions
- Does Alaska have a stem cell law?
- No. Alaska has no stem cell authorization law, disclosure law, or documentation statute. Its Right to Try Act (HB 43, 2018) is sometimes raised in this context, but it is a terminal-illness access law for investigational products past Phase 1 trials and names no cell or tissue category. Exosome products in Alaska are governed by federal law, under which no exosome product is FDA-approved for administration to humans.
- Can a nurse practitioner run a practice in Alaska without a physician?
- Yes. Alaska advanced practice registered nurses are licensed independent practitioners: no collaborative agreement or physician protocol is required, and an APRN holds independent prescriptive authority, including controlled substances with the board’s authorization. An APRN-led practice evaluates and orders within its own scope, and a physician is involved where a procedure falls outside that scope or a payer requires one.
- Does an Alaska practice need a resale certificate to buy for resale?
- There is no statewide one to get, because Alaska levies no statewide sales tax. Municipalities may levy their own local sales taxes, so a practice in a city or borough with one keeps its municipal registration and resale documentation in order. The Department of Revenue Tax Division administers state-level taxes, none of which is a general sales tax.
- Does my Alaska clinic need a wholesale distributor license to buy exosomes?
- No. The nonresident wholesale drug distributor license under 12 AAC 52 is held by the distributor shipping into Alaska, not by the practice buying. Your practice orders against its own professional license and NPI. Licensure for shipping into the state is held by the entities that ship: our 503A pharmacy partner for compounded preparations, and a registered tissue bank licensed to ship to all 50 states and Puerto Rico for exosome material.
- Are exosomes FDA approved?
- No exosome product has been approved by the FDA for administration to humans, and the FDA said so directly in its 2019 public safety notification on exosome products. ExaVeyra supplies Kimera exosome material for topical aesthetic use by licensed practitioners, with a Certificate of Analysis and lot traceability on every vial.
- How long does cold-chain shipping take to Alaska?
- Ships from Florida by overnight shipping, and arrival can take one to three business days. All exosome shipments travel cold-chain with validated temperature monitoring. A shipment in transit over a weekend waits in the carrier network, so a practice that will be closed orders around the closure. Practices beyond the Anchorage, Fairbanks, and Juneau hub areas allow for the connecting air leg.
Sources
Last reviewed 16 October 2026 by ExaVeyra Sciences editorial team. Every claim above links to a primary source.
- Notice of adopted changes to Board of Pharmacy regulations, 12 AAC 52 (nonresident licensing categories, effective 31 October 2019) (accessed 16 October 2026)
- Alaska Statutes, legislature statutes portal (Title 8) (accessed 16 October 2026)
- Alaska Board of Pharmacy (accessed 16 October 2026)
- Alaska State Medical Board (accessed 16 October 2026)
- Alaska Board of Nursing (accessed 16 October 2026)
- Alaska Department of Revenue, Tax Division (accessed 16 October 2026)
- FDA Public Safety Notification on Exosome Products (accessed 16 October 2026)
Scientific literature
Peer-reviewed references, each with its study design and, for human studies, the number of participants, so a reader can judge the weight of a citation without opening it. None is a claim about any product.
- Welsh JA, Goberdhan DCI, O’Driscoll L, et al. Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches. Journal of Extracellular Vesicles, 2024. doi:10.1002/jev2.12404 PMID:38326288Clinical guidelinesupports: Defines the current characterization and reporting standard for extracellular vesicles, the benchmark behind the COA and lot documentation this page describes.
- Théry C, Witwer KW, Aikawa E, et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. Journal of Extracellular Vesicles, 2018. doi:10.1080/20013078.2018.1535750 PMID:30637094Clinical guidelinesupports: The landmark EV characterization standard that MISEV2023 updates; together they set what a complete exosome characterization package contains.
- Phinney DG, Pittenger MF. Concise Review: MSC-Derived Exosomes for Cell-Free Therapy. Stem Cells, 2017. doi:10.1002/stem.2575 PMID:28294454Narrative reviewsupports: Reviews mesenchymal stromal cells as a source of exosomes, context for the perinatal MSC-derived EV source material this page describes.
These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease. There are no FDA-approved exosome products. Biomolecular signaling vesicle products distributed by ExaVeyra Sciences are supplied for topical aesthetic use by licensed practitioners and for laboratory and IND-authorized clinical research, and are not tissue products as defined by FDA guidelines.